MetaVia Announces Late-Breaking Poster Presentation on DA-1241
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company, has recently shared exciting news about its innovative treatment DA-1241, a G-Protein-Coupled Receptor 119 (GPR119) agonist. This groundbreaking drug is advancing in the fight against cardiometabolic diseases. The company announced that an abstract from their Phase 2a clinical trial focusing on DA-1241 has been accepted for a late-breaking poster presentation at a prestigious upcoming congress.
Details of the Presentation at EASL Congress
The presentation is scheduled to take place at the European Association for the Study of the Liver (EASL) Congress 2025. Attendees can expect to hear insights from the clinical trial, particularly its findings related to metabolic dysfunction-associated steatohepatitis (MASH). This important meeting will allow researchers, clinicians, and industry experts to converge and discuss advances in liver disease treatments and concepts.
Title and Abstract Synopsis
The title of the poster presentation is DA-1241, a GPR119 Agonist, Demonstrates Hepatoprotective and Glucose-Regulating Effects in a 16-week Randomized Placebo-Controlled Trial in Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients. The presenting author for this research is Dr. Rohit Loomba, a distinguished professor in the field of gastroenterology.
Key Results and Findings
During the trial period, DA-1241 showcased significant liver protective qualities and glucose-regulating effects. Such findings support DA-1241's potential as an effective treatment for patients dealing with MASH, a condition that requires urgent therapeutic options due to its complications. The session will provide detailed insights into these outcomes, highlighting how DA-1241 impacts patients’ health positively.
A Comprehensive Look at DA-1241
DA-1241 operates by promoting the release of vital gut hormones such as GLP-1 and GIP, which are crucial for appetite suppression and enhancing the metabolism of glucose and lipids. The drug’s beneficial effects on liver function and metabolic processes have been promising during preclinical studies. MetaVia's commitment to developing solutions for chronic metabolic disorders is illustrated by the positive results seen in animal models of MASH and type 2 diabetes (T2D).
Clinical Trials and Efficacy
In early-phase clinical trials, DA-1241 exhibited a good safety profile and tolerability among subjects, including both healthy individuals and patients with T2D. The results from the Phase 2a study demonstrate DA-1241’s dual action not only in glucose regulation but also in providing direct hepatic benefits, which are vital for a comprehensive treatment strategy for metabolic diseases.
About MetaVia Inc.
MetaVia Inc. stands at the forefront of transforming treatments for cardiometabolic diseases. In addition to its work with DA-1241, the company is also developing DA-1726 as a treatment aimed at tackling obesity. DA-1726 is distinguished by its dual agonistic action on glucagon-like peptide-1 and glucagon receptors, indicating a deepened commitment to innovative therapeutic approaches.
The Future of Treatment for MASH and T2D
With their innovative therapies, MetaVia aims to redefine treatment paradigms for those facing metabolic dysfunctions. Research continues to support the capability of DA-1241 not only in managing symptoms but also in altering the disease trajectory. By attending forums such as the EASL Congress, the company will disseminate valuable information and connect with leading figures in the healthcare community.
Frequently Asked Questions
What is DA-1241?
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, developed to treat metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes.
When will the presentation take place?
The late-breaking poster presentation will be held from May 7-10, 2025, during the EASL Congress.
Who is the presenting author?
Dr. Rohit Loomba, a professor in gastroenterology, will present the results of the clinical trial.
What are the expected outcomes of DA-1241?
DA-1241 is anticipated to offer hepatoprotective and glucose-regulating benefits to patients, based on preliminary trial findings.
How can I find more information about MetaVia?
For additional details about the company and its innovative therapies, please visit their official website.
